Orexo changes the organizational structure and management team to increase focus on development of new products
Rhea-AI Summary
Orexo (OTCQX:ORXOY / STO:ORX, ADR: ORXOF) announced organizational and management changes on March 6, 2026 following the divestment of Zubsolv in the US and a renewed focus on advancing development programs and the AmorphOX technology.
Lisa Moore will become SVP, Products and Portfolio Strategy, reporting to the CEO and joining the management team; Robert DeLuca will retire from his President, Orexo US Inc. role in May 2026 and continue in an advisory capacity for the Zubsolv transition. Orexo will present at its R&D Day on March 24, 2026.
Positive
- Strategic shift to R&D focus on AmorphOX and development programs
- Appointment of Lisa Moore as SVP, Products and Portfolio Strategy to drive product vision
- Planned continuity: Robert DeLuca to support transition through May 2026 and advisory role
Negative
- Divestment of Zubsolv in the US reduces direct commercial presence in a key market
- Potential short-term loss of US commercial revenue stream following the Zubsolv transition
Key Figures
Market Reality Check
Peers on Argus
ORXOF is up 5.9% while close peers like BIOYF (-5.56%) and PLNH (-0.78%) are down, and ORXOY is flat, indicating a stock-specific move rather than a sector shift.
Market Pulse Summary
This announcement outlines leadership changes and a sharpened focus on pipeline development and AmorphOX®, set against a technically supportive backdrop with shares above the 200-day MA of 1.51. Investors may track execution on product development, the transition of Zubsolv® US, and upcoming events such as the March 24 R&D Day. With limited historical news-reaction data, future disclosures and operational milestones could be key reference points.
AI-generated analysis. Not financial advice.
UPPSALA,
Maintaining commercial and US market competence is important to ensure new products are developed to address unmet customer needs. Lisa Moore, who has been part of Orexo's US leadership team since May 2024, will assume a new responsibility as Senior Vice President, Products and Portfolio Strategy. In her new role, she will be responsible for driving the long-term product vision for the development candidates, ensuring that the portfolio meets customer needs and that investment decisions support business growth.
Lisa Moore is a biopharma industry leader with more than 25 years of experience in commercial, new product planning, and strategy roles. Prior to joining Orexo in 2024, she was Vice President, Global Commercial Strategy at Emergent, where she also led the commercial valuation of M&A opportunities. She has previously held management positions at MedImmune, Parke-Davis, Baxter International, and Merck. Lisa Moore will be a part of Orexo´s management team and report directly to the CEO. She will participate in Orexo's R&D Day on March 24 in
Robert DeLuca, President of Orexo US Inc. since the launch of the US commercial organization in 2013, has been instrumental in building the US business, leading the successful commercialization of Zubsolv and advancing Orexo's mission to help curb the US opioid epidemic. Robert DeLuca will retire from his role at the company.
Nikolaj Sorensen, CEO & President of Orexo, said: "As Orexo enters a new chapter, we are aligning our organization to best support our long-term priorities and value creation ambitions. These changes sharpen our focus on advancing our pipeline, unlocking the potential of AmorphOX, and building strong strategic partnerships. As we enter this next phase, I also want to express my sincere gratitude to Bob DeLuca. Over more than a decade, Bob has been a close business partner and an outstanding leader, playing a pivotal role in building our US business and bringing Zubsolv to patients. His commitment, integrity, and impact on Orexo will be lasting, and I am personally thankful for our many years of close collaboration."
Robert DeLuca will continue in his role as President of Orexo US Inc. through May 2026. He will also, after May continue to support the company with strategic projects and with the transition of Zubsolv® US to Dexcel Pharma
For further information contact:
Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
+46 (0)18 780 88 00
ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala,
For more information, please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
The information was submitted for publication at 3.30 pm CET on March 6, 2026.
CONTACT:
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://news.cision.com/orexo/i/orexo-lisa-moore-svp-product-and-portfolio-strategy-,c3517346 | orexo-lisa-moore SVP Product and Portfolio Strategy |
View original content:https://www.prnewswire.com/news-releases/orexo-changes-the-organizational-structure-and-management-team-to-increase-focus-on-development-of-new-products-302706829.html
SOURCE Orexo
FAQ
Why did Orexo (ORXOF) change its organizational structure on March 6, 2026?
What is Lisa Moore's new role at Orexo (ORXOF) and when does she join management?
When will Robert DeLuca leave his role as President of Orexo US Inc. (ORXOF)?
How does the Zubsolv divestment affect Orexo's US commercial presence (ORXOF)?
Will Orexo present investor or pipeline updates after the March 6, 2026 announcement?
